
    
      This is an open-label study to assess the long-term safety and efficacy of pegunigalsidase
      alfa treatment of 2.0 mg/kg administered intravenously every 4 weeks. The duration of
      treatment will be up to 36 months or until pegunigalsidase alfa is available to the patient
      at the discretion of the Sponsor. Interim analyses may be performed for administrative
      purposes during the conduct of the study.
    
  